Smegglutide is a long-acting incretin preparation. Its weight loss mechanism has two core mechanisms:

1. Central appetite suppression: It acts on the brain's feeding center, reducing hunger at its source, making you naturally less inclined to eat.

2. Delayed gastric emptying: Food stays in the stomach longer, resulting in a prolonged feeling of fullness, making you feel full after eating only a small amount.

The combined effect of these two mechanisms helps reduce daily food intake, thereby achieving weight loss. The effectiveness of smegglutide injections for weight loss varies from person to person. Clinical data shows that after 68 weeks of continuous use, users experienced an average weight loss of 17% and an average waist circumference reduction of 15.8 cm, with the greater the initial weight gain, the more significant the weight loss. Approximately 10% of users experience primary failure, with little or no weight loss after using the medication.

Clinical data also shows that more than half of users experience weight rebound after discontinuing the medication. However, the core reason for this rebound is not drug dependence, but rather a return to unhealthy lifestyle habits-overeating, high-fat and high-sugar diets, and a sedentary lifestyle. The only way to avoid weight rebound is to adhere to a healthy lifestyle intervention during and after medication. If a healthy diet and regular exercise are maintained after stopping medication, weight not only will not rebound, but it may continue to decrease slowly. If weight rebounds within six months, medication can be restarted under the guidance of a doctor; if more than six months have passed, a risk assessment at the hospital is necessary.

Potential Organ Protection:

1. Liver protection: Inhibits the ROS/NF-κB/NLRP3 inflammatory pathway, reducing the release of pro-inflammatory cytokines; enhances PINK1/Parkin mitophagy, alleviating 5-fluorouracil-induced liver damage;

2. Kidney protection: Reduces the urinary albumin/creatinine ratio (UACR) in diabetic patients, possibly related to inhibiting renal interstitial inflammation and reducing glomerular sclerosis.